Nuocheng Jianhua and Shanghai Pharmaceutical Science Park reach strategic cooperation

January 16, 2021

Beijing, January 13, 2021 / AP / -- a biomedical high-tech company, nuocheng Jianhua (stock exchange of Hong Kong Code: 09969), has reached a strategic cooperation with Shanghai Pharmaceutical Science Park Xinhai Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceutical Science Park") in Beijing today. The two sides will cooperate in drug distribution, DTP (direct to We will cooperate deeply in pharmacy layout, inter provincial business collaboration, third-party logistics services, and patient services, and support nuocheng Jianhua's approved Btk inhibitor obutinib tablets (Product Name: yinuokai) to reach patients quickly, so as to improve the accessibility and convenience of patients.

On December 25, 2020, yinuokai was approved by the State Drug Administration of China (nmpa) for the treatment of patients with relapsed / refractory chronic lymphoblastic leukemia (CLL) / small lymphocytic lymphoma (SLL) and relapsed / refractory mantle cell lymphoma (MCL).

Based on the integrated biomedical platform, ncjh is committed to developing innovative drugs for malignant tumors and autoimmune diseases. In addition to the approval of the first innovative drug, obutinib, ncjh has built more than 10 balanced R & D pipelines, three of which are in clinical stage.

As the core carrier of the northern business platform of Shanghai Pharmaceutical Group, Shanghai Pharmaceutical Science Park is a large-scale comprehensive service pharmaceutical business enterprise integrating hospital drug sales, cross regional drug distribution, retail and patient service, and third-party logistics, with more than 10 enterprises in Beijing, Hubei, Shaanxi, Henan, Liaoning, Jilin, Heilongjiang, Hebei, Inner Mongolia, Hainan and other regions Provincial platform.

문의하기

Author:

Ms. Yi

Phone/WhatsApp:

+8618888297294